This treatment embodies the core of the DRC360 mission: providing targeted, effective therapies that address fundamental aspects of cellular health to help patients achieve a state of true wholeness and optimal function in their daily lives
Distribution favors metabolically active organs, particularly the kidneys, liver, stomach wall, and intestinal tissues
Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury
70 HP 130 AOD-9604 HGH Fragment 176-191 Lipolytic ALIASES AOD-9604, AOD9604, hGH(176-191), Tyr-hGH(177-191) CLASS Synthetic growth-hormone C-terminal fragment lipolytic candidate FORMULA CHNOS SEQUENCE 16-residue fragment corresponding to hGH(177-191) with N-terminal Tyrosine addition HALF-LIFE Short (minutes) plasma ROUTES Subcutaneous (Phase 2 obesity) Oral (food-supplement contexts in some jurisdictions) MECHANISM OF ACTION Synthetic 15-amino-acid fragment of human growth hormone (residues 176-191)
Dose and Frequency Published research consistently uses daily dosing at 10 g/kg in rats (human equivalent ~200300 g/day via allometric scaling)
Find more products here Visit Our Instagram Page Share your thoughts
